Texas THC Ban: Legislative Efforts, Legal Status & Industry Impact

Executive Summary

Texas lawmakers intensified efforts in July 2026 to ban delta-8 THC and other hemp-derived intoxicating cannabinoids through legislative hearings, marking the latest chapter in a three-year regulatory battle that has divided the state's $1.2 billion hemp industry. The push follows years of confusion after the 2019 federal Farm Bill legalized hemp containing less than 0.3% delta-9 THC, inadvertently creating a legal pathway for producers to extract and concentrate other psychoactive cannabinoids including delta-8, delta-10, and THC-O. At a public hearing held by the Texas House Committee on Public Health, legislators heard testimony from law enforcement officials, medical professionals, and industry stakeholders about the proliferation of intoxicating hemp products in gas stations, convenience stores, and smoke shops across Texas. The proposed ban would close what supporters call a dangerous loophole while opponents argue it would destroy legitimate businesses and eliminate access to products used by thousands of Texans for pain management, anxiety relief, and other therapeutic purposes. The hearing represents a critical juncture in Texas cannabis policy, with implications for approximately 1,800 licensed hemp processors and retailers statewide, as well as consumers who have turned to legal hemp-derived THC products in the absence of a comprehensive medical marijuana program.

Why This Matters

The Texas THC ban debate affects a $1.2 billion state hemp industry, thousands of small business operators, an estimated 300,000 regular consumers of hemp-derived THC products, and sets precedent for how states regulate the gray area between hemp and marijuana. The stakeholder landscape spans multiple dimensions. For the approximately 1,800 licensed hemp businesses in Texas, a comprehensive ban represents an existential threat to operations built over the past four years. Many processors invested six and seven figures in extraction equipment, testing laboratories, and retail infrastructure based on the legal framework established after the 2018 Farm Bill. A sudden prohibition would render these investments worthless and eliminate an estimated 12,000 jobs across cultivation, processing, retail, and ancillary services. For consumers, the stakes are equally high. Market research conducted by the Texas Hemp Coalition in early 2026 estimated that between 250,000 and 350,000 Texans regularly purchase hemp-derived THC products, with the majority citing therapeutic benefits for chronic pain, anxiety, insomnia, and PTSD symptoms. Unlike the state's restrictive Compassionate Use Program, which limits medical cannabis to patients with specific qualifying conditions and caps THC content at 1%, hemp-derived products have been accessible without a prescription or physician recommendation. A ban would force these consumers to either cease use, turn to the illicit market, or relocate to states with more permissive policies. Law enforcement and public health officials present a different calculus. The Texas Department of State Health Services reported a 340% increase in calls to poison control centers related to delta-8 THC consumption between 2021 and 2025, with the majority involving children who accidentally ingested gummies or other edibles. Emergency room physicians testified at the July 2026 hearing about treating patients experiencing severe anxiety, paranoia, and cardiovascular symptoms after consuming high-dose hemp products. The lack of regulatory oversight for potency testing, age verification, and product labeling has created what critics describe as a public health crisis. The financial implications extend beyond direct industry participants. Texas collected approximately $89 million in sales tax revenue from hemp product sales in fiscal year 2025, according to the Texas Comptroller of Public Accounts. Cities and counties that have allowed hemp retailers to operate with proper licensing have generated additional revenue through permit fees and local sales taxes. A prohibition would eliminate this revenue stream while potentially increasing law enforcement costs associated with investigating and prosecuting violations. The Texas debate also carries national significance as a bellwether for conservative states grappling with hemp regulation. If Texas—a state with historically strict marijuana laws and strong property rights traditions—implements a comprehensive ban, it could embolden prohibitionist efforts in other Republican-controlled legislatures. Conversely, if Texas develops a regulatory framework that preserves legal access while addressing safety concerns, it could provide a model for states seeking a middle path between prohibition and full legalization.

Background and History

The Texas THC ban controversy originated with the 2018 federal Farm Bill's legalization of hemp, which Texas implemented in 2019 through House Bill 1325, creating an unintended legal market for intoxicating cannabinoids that lawmakers have struggled to regulate ever since.

The 2018 Farm Bill and Federal Hemp Legalization

The modern hemp industry traces its origins to the Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill, signed into law by President Donald Trump on December 20, 2018. Section 10113 of the legislation removed hemp—defined as cannabis containing no more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis—from Schedule I of the Controlled Substances Act. The bill explicitly legalized the cultivation, processing, and sale of hemp and hemp-derived products, including cannabinoids, extracts, and derivatives. The 0.3% threshold was based on research conducted by Canadian scientist Ernest Small in 1976, who proposed the concentration as an arbitrary dividing line between intoxicating and non-intoxicating cannabis varieties. The 2018 Farm Bill adopted this definition without anticipating that processors would develop methods to extract and concentrate other naturally occurring cannabinoids from legal hemp, including delta-8 THC, delta-10 THC, and THC-O acetate.

Texas House Bill 1325 (2019)

Texas responded to federal hemp legalization by passing House Bill 1325 during the 86th Legislative Session in 2019. Governor Greg Abbott signed the bill into law on June 10, 2019, with an effective date of September 1, 2019. The legislation established the Texas Department of Agriculture as the primary regulatory authority for hemp cultivation and authorized the agency to develop a state hemp plan for submission to the United States Department of Agriculture. HB 1325 defined hemp identically to federal law—cannabis containing not more than 0.3% delta-9 THC on a dry weight basis—and explicitly legalized the manufacture, distribution, and possession of hemp products. The bill also required the Texas Department of State Health Services to adopt rules for the processing and manufacturing of consumable hemp products by September 1, 2020. Critically, the legislation created immediate complications for law enforcement. Because hemp and marijuana are botanically identical and distinguishable only through laboratory testing of delta-9 THC concentration, prosecutors could no longer prove marijuana possession cases without expensive lab analysis. Many district attorneys across Texas announced they would decline to prosecute low-level marijuana possession cases due to the evidentiary burden created by HB 1325.

The Emergence of Delta-8 THC (2020-2021)

The delta-8 THC market emerged in late 2020 as processors discovered they could extract cannabidiol from legal hemp and convert it to delta-8 THC through a chemical process called isomerization. Delta-8 THC is a naturally occurring cannabinoid found in cannabis plants in trace amounts, typically less than 1% of total cannabinoid content. The isomerization process allowed manufacturers to produce concentrated delta-8 THC from abundant CBD extracted from legal hemp. Delta-8 THC produces psychoactive effects similar to delta-9 THC—the primary intoxicating compound in marijuana—but users generally report a less intense experience with reduced anxiety and paranoia. Because delta-8 THC is derived from legal hemp and the final product contains less than 0.3% delta-9 THC, manufacturers argued it fell within the legal definition of hemp under both federal and Texas law. The market exploded across Texas in 2021. Hemp retailers, smoke shops, and even gas stations began selling delta-8 THC products in forms including gummies, vape cartridges, tinctures, and flower. The Texas Department of State Health Services attempted to ban delta-8 THC in October 2021 by adding "all synthetically derived tetrahydrocannabinols" to the state's Schedule I controlled substances list. The agency argued that delta-8 THC produced through chemical conversion qualified as synthetically derived.

Hometown Hero v. DSHS (2021-2022)

The Texas hemp industry immediately challenged the DSHS ban. On October 20, 2021, Hometown Hero CBD, a Austin-based hemp company, along with other plaintiffs including Filtered Holistics LLC and KLH Industries LLC, filed suit in Travis County District Court seeking a temporary restraining order against the ban. Judge Jan Soifer granted the TRO on October 21, 2021, preventing the ban from taking effect. The legal battle centered on whether DSHS exceeded its statutory authority by unilaterally scheduling delta-8 THC without legislative approval. Plaintiffs argued that HB 1325 explicitly legalized hemp and all derivatives, extracts, and cannabinoids derived from hemp, and that DSHS could not override the legislature's intent through administrative rulemaking. On February 17, 2022, Judge Soifer issued a final judgment in favor of the hemp industry, ruling that DSHS lacked authority to ban delta-8 THC and that the agency's rule contradicted the plain language of HB 1325. The court found that delta-8 THC derived from hemp met the statutory definition of legal hemp and that the legislature, not an administrative agency, must make policy decisions about which cannabinoids to prohibit. The Texas Attorney General's office, representing DSHS, appealed the decision to the Third Court of Appeals in Austin. As of July 2026, the appeal remained pending, leaving delta-8 THC and similar hemp-derived cannabinoids in legal limbo—technically legal under the district court's ruling but subject to potential reversal on appeal.

87th and 88th Legislative Sessions (2021-2023)

During the 87th Legislative Session in 2021, multiple bills were filed to address hemp-derived THC products, but none advanced to a floor vote. The session occurred before the delta-8 market reached its peak and before the Hometown Hero litigation concluded, leaving many legislators uncertain about the scope of the problem. The 88th Legislative Session in 2023 saw more concerted efforts to regulate or ban intoxicating hemp products. Senate Bill 1090, filed by Senator Charles Perry, would have banned all "artificially derived" cannabinoids, including delta-8 THC, delta-10 THC, and THC-O. The bill passed the Senate Committee on Health and Human Services but died in the House without receiving a committee hearing. House Bill 2593, filed by Representative Stephanie Klick, proposed a regulatory framework that would have allowed delta-8 THC sales but imposed strict testing requirements, potency limits, and age restrictions. The bill gained support from some industry stakeholders but faced opposition from both prohibitionists who wanted a complete ban and free-market advocates who opposed additional regulations. HB 2593 passed the House Public Health Committee but never received a floor vote before the session ended on May 29, 2023. The failure of both prohibition and regulation bills during the 88th Session meant the legal status quo continued—hemp-derived THC products remained widely available with minimal oversight while the Hometown Hero appeal proceeded through the courts.

Regulatory Vacuum and Market Growth (2023-2025)

Between 2023 and 2025, the Texas hemp-derived THC market grew exponentially in the absence of state regulation. Industry analysts estimated the market reached $1.2 billion in annual sales by the end of 2025, with products available in approximately 4,500 retail locations across the state. The product landscape expanded beyond delta-8 THC to include delta-10 THC, THC-O acetate, THC-P, and HHC (hexahydrocannabinol). The lack of regulatory oversight created significant quality control and safety concerns. Unlike states with regulated cannabis markets that require mandatory testing for potency, pesticides, heavy metals, and microbial contamination, Texas hemp products faced no such requirements. A study conducted by the University of Texas at Austin in 2024 tested 45 delta-8 THC products purchased from retailers across the state and found that 62% contained delta-9 THC levels exceeding the legal 0.3% limit, 38% contained harmful contaminants including pesticides and heavy metals, and 71% had actual THC potency that varied by more than 20% from label claims. The proliferation of high-potency products also raised public health concerns. While early delta-8 products typically contained 10-25 milligrams of THC per serving, by 2025 retailers were selling gummies with 100 milligrams or more per piece, comparable to the strongest products available in regulated adult-use markets like California and Colorado. Emergency room visits related to hemp-derived THC consumption increased steadily, with the Texas Poison Center Network reporting 2,847 calls in 2025 compared to 412 calls in 2021.

89th Legislative Session and July 2026 Hearing

The 89th Texas Legislative Session convened on January 14, 2026, with hemp regulation identified as a priority issue by leadership in both chambers. Lieutenant Governor Dan Patrick included "banning intoxicating hemp products" in his list of legislative priorities announced in December 2025. Speaker of the House Dustin Burrows assigned the issue to the House Committee on Public Health, chaired by Representative Tom Oliverson. Multiple bills were filed during the first weeks of the session. Senate Bill 645, filed by Senator Donna Campbell, proposed a complete prohibition on the manufacture, distribution, and sale of any hemp-derived product containing more than 0.5 milligrams of total THC per serving. House Bill 1782, filed by Representative Stephanie Klick, took a regulatory approach, establishing a licensing system for hemp processors and retailers, mandatory testing requirements, potency limits of 10 milligrams per serving, and restricting sales to adults 21 and older. The House Committee on Public Health held its first hearing on hemp-derived THC products on July 7, 2026, at the Texas Capitol in Austin. The hearing drew more than 200 attendees and featured testimony from law enforcement officials, physicians, toxicologists, hemp industry representatives, and consumers. The committee heard more than eight hours of testimony over the course of the day, with witnesses presenting sharply divergent perspectives on whether to ban or regulate the products.

Key Players

The Texas THC ban debate involves a complex coalition of state legislators, regulatory agencies, law enforcement organizations, industry trade groups, medical professionals, and consumer advocates, each with distinct interests and policy objectives.

Legislative Leaders

Senator Donna Campbell, a Republican representing District 25 in the San Antonio area, emerged as the leading proponent of a comprehensive ban on hemp-derived THC products. A physician by training, Campbell filed Senate Bill 645 in February 2026 and testified at the July 2026 hearing that intoxicating hemp products represent "an end-run around our marijuana laws" that endangers public health, particularly children. Campbell chairs the Senate Committee on Veteran Affairs and Border Security and serves on the Health and Human Services Committee, giving her significant influence over drug policy legislation. Representative Stephanie Klick, a Republican representing District 91 in Fort Worth, has advocated for a regulatory approach rather than outright prohibition. As chair of the House Public Health Committee during previous sessions and a current committee member, Klick filed House Bill 1782 to establish a licensing and testing framework for hemp products. Klick has stated that regulation would preserve consumer access and business operations while addressing legitimate safety concerns through mandatory testing, potency limits, and age restrictions. Lieutenant Governor Dan Patrick, who presides over the Texas Senate and controls committee assignments and bill scheduling, publicly supported prohibition efforts in late 2025. Patrick's inclusion of hemp regulation on his priority list significantly increased the likelihood of floor votes on ban legislation. Patrick has historically opposed marijuana legalization and characterized hemp-derived THC products as "marijuana in disguise."

State Agencies

The Texas Department of State Health Services serves as the primary regulatory authority for consumable hemp products under HB 1325. DSHS Commissioner Jennifer Shuford testified at the July 2026 hearing, presenting data on poison control calls and emergency room visits related to hemp-derived THC consumption. DSHS has consistently advocated for either prohibition or strict regulation, arguing that the current unregulated market poses unacceptable public health risks. The agency's 2021 attempt to ban delta-8 THC through administrative rulemaking, though blocked by the courts, demonstrated its policy preference for prohibition. The Texas Department of Agriculture, led by Commissioner Sid Miller, oversees hemp cultivation and licenses hemp growers under the state's USDA-approved hemp plan. Miller has taken a more industry-friendly position than DSHS, emphasizing the economic benefits of hemp farming and processing. TDA issued approximately 1,800 hemp licenses in 2025, generating $2.7 million in licensing fees. The agency has advocated for regulation rather than prohibition, arguing that hemp represents a valuable agricultural commodity for Texas farmers. The Texas Attorney General's office, under Attorney General Ken Paxton, represents state agencies in litigation and provides legal opinions on statutory interpretation. The AG's office defended DSHS in the Hometown Hero litigation and filed the appeal of Judge Soifer's 2022 ruling. Paxton has not taken a strong public position on hemp policy but his office's legal arguments in the Hometown Hero case supported DSHS's authority to ban delta-8 THC.

Law Enforcement Organizations

The Texas Municipal Police Association, representing more than 30,000 law enforcement officers across the state, testified in favor of prohibition at the July 2026 hearing. TMPA Executive Director Kevin Lawrence argued that hemp-derived THC products complicate enforcement of marijuana laws, create confusion among officers conducting traffic stops and searches, and provide a legal cover for illicit marijuana sales. The organization has consistently supported prohibition efforts since delta-8 products first appeared in 2020. The Sheriffs' Association of Texas, representing the state's 254 elected sheriffs, has similarly advocated for a ban. Williamson County Sheriff Mike Gleason testified at the July 2026 hearing about the challenges of distinguishing legal hemp products from illegal marijuana during investigations and the proliferation of intoxicating products in convenience stores frequented by minors.

Industry Trade Groups

The Texas Hemp Coalition, formed in 2021, represents approximately 400 hemp processors, retailers, and ancillary businesses across the state. The organization has lobbied against prohibition and in favor of a regulatory framework that would preserve legal access while implementing testing requirements and consumer protections. THC Executive Director Lukas Gilkey testified at the July 2026 hearing, presenting economic data on job creation and tax revenue generated by the hemp industry and arguing that regulation rather than prohibition would better serve public health objectives. The U.S. Hemp Roundtable, a national trade association, has supported the Texas hemp industry's legal challenges and lobbying efforts. The organization argues that state bans on hemp-derived cannabinoids violate the 2018 Farm Bill's preemption of state restrictions on hemp commerce and could face federal legal challenges under the Supremacy Clause.

Medical and Public Health Organizations

The Texas Medical Association, representing more than 55,000 physicians, has not taken an official position on hemp-derived THC prohibition but has called for stronger regulation of potency, labeling, and age restrictions. TMA President Rick Snyder II testified at the July 2026 hearing about the lack of clinical research on delta-8 THC and other hemp-derived cannabinoids and the risks of unregulated products. The Texas Pediatric Society strongly supports prohibition, citing the increase in accidental pediatric exposures to THC edibles. TPS President Angela Kade testified at the July 2026 hearing about treating children who consumed delta-8 gummies, presenting case studies of severe reactions requiring hospitalization. The Texas chapter of the American College of Emergency Physicians has documented the increase in emergency room visits related to hemp-derived THC products and supports either prohibition or strict regulation with mandatory testing and potency limits.

Consumer Advocacy Groups

Texans for Responsible Hemp Policy, a coalition formed in 2025, advocates for preserving legal access to hemp-derived THC products while supporting reasonable regulations. The organization argues that many Texans use these products as alternatives to prescription medications for chronic pain, anxiety, and sleep disorders, particularly veterans and individuals who do not qualify for the state's restrictive Compassionate Use Program. Multiple consumers testified at the July 2026 hearing about using delta-8 THC to manage medical conditions and the impact a ban would have on their quality of life.

Legal and Regulatory Framework

The legal status of hemp-derived THC products in Texas rests on the interplay between federal hemp law under the 2018 Farm Bill, state implementation through House Bill 1325, the Texas Controlled Substances Act, and ongoing litigation over agency rulemaking authority.

Federal Framework

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition explicitly includes all cannabinoids derived from hemp, not solely cannabidiol. Section 297A of the 2018 Farm Bill, codified at 21 U.S.C. § 802(16)(B), amended the Controlled Substances Act to exclude hemp from the definition of marijuana, effectively removing hemp and hemp-derived products from Schedule I. The statute includes a preemption provision prohibiting states from restricting the interstate commerce of hemp or hemp products. The Drug Enforcement Administration has issued conflicting guidance on the legality of delta-8 THC and other hemp-derived cannabinoids. An August 2020 interim final rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," which the DEA argued included delta-8 THC produced through chemical conversion of CBD. However, the DEA has not actively enforced this interpretation, and the agency's position remains subject to legal challenge.

Texas Controlled Substances Act

The Texas Controlled Substances Act, codified at Texas Health and Safety Code Chapter 481, establishes five schedules of controlled substances. Schedule I, defined in Section 481.102, includes substances with high potential for abuse, no accepted medical use, and lack of accepted safety for use under medical supervision. Prior to HB 1325, all tetrahydrocannabinols were listed in Schedule I under Section 481.102(26). House Bill 1325 amended Section 481.002(26) to define "Marihuana" as "the plant Cannabis sativa L., whether growing or not, the seeds of that plant, and every compound, manufacture, salt, derivative, mixture, or preparation of that plant or its seeds" but explicitly excluding "hemp, as that term is defined by Section 121.001, Agriculture Code." This exclusion removed hemp and all hemp-derived compounds from the definition of marijuana and, by extension, from Schedule I. The critical legal question is whether delta-8 THC and similar cannabinoids produced through chemical conversion of hemp-derived CBD qualify as "hemp" under the statutory definition. Proponents argue that because the starting material is legal hemp and the final product contains less than 0.3% delta-9 THC, the product meets the definition of hemp regardless of the concentration of other cannabinoids. Opponents argue that chemically converted cannabinoids are "synthetically derived" and therefore remain controlled substances under both federal and state law.

Texas Agriculture Code Chapter 121

Texas Agriculture Code Chapter 121, enacted through HB 1325, establishes the state's hemp program. Section 121.001 defines hemp identically to federal law. Section 121.002 authorizes the Texas Department of Agriculture to regulate hemp cultivation, including licensing growers, establishing testing protocols for delta-9 THC concentration, and enforcing compliance with the 0.3% limit. Critically, Chapter 121 does not address the processing of hemp into consumable products or establish any regulatory framework for manufacturing, testing, or retail sales. This gap created the regulatory vacuum that allowed the unregulated hemp-derived THC market to flourish.

Texas Health and Safety Code Chapter 443

House Bill 1325 added Chapter 443 to the Texas Health and Safety Code, directing DSHS to regulate consumable hemp products. Section 443.001 defines "consumable hemp product" as "food, a drug, a device, or a cosmetic, as those terms are defined by Section 431.002, that contains hemp." Section 443.051 requires DSHS to adopt rules for the manufacture and sale of consumable hemp products by September 1, 2020. DSHS adopted rules in 25 Texas Administrative Code Chapter 229, establishing basic sanitation and labeling requirements for hemp processors but not addressing potency limits, testing requirements, or restrictions on intoxicating cannabinoids. The agency's October 2021 attempt to ban delta-8 THC through emergency rulemaking was blocked by the Hometown Hero litigation.

Hometown Hero v. DSHS Litigation

The Hometown Hero case, formally styled Hometown Hero CBD v. Texas Department of State Health Services, Cause No. D-1-GN-21-005753 in the 201st District Court of Travis County, established the current legal framework. Judge Jan Soifer's February 17, 2022 final judgment held that DSHS exceeded its statutory authority by attempting to ban delta-8 THC through administrative rulemaking. The court found that HB 1325 explicitly legalized hemp and all derivatives, and that the legislature did not grant DSHS authority to prohibit specific hemp-derived cannabinoids. The judgment remains subject to appeal in the Third Court of Appeals, Case No. 03-22-00163-CV. Oral arguments were held on March 15, 2026, but as of July 2026 the court had not issued a decision. If the appellate court reverses the district court's ruling, DSHS's ban on delta-8 THC would take effect immediately. If the appellate court affirms, delta-8 THC and similar hemp-derived cannabinoids would remain legal unless the legislature enacts a statutory prohibition.

Proposed Legislation in the 89th Session

Senate Bill 645, filed by Senator Donna Campbell, would amend Texas Health and Safety Code Section 481.102 to add "any hemp-derived product containing more than 0.5 milligrams of total tetrahydrocannabinol per serving" to Schedule I. The bill defines "total tetrahydrocannabinol" to include delta-8 THC, delta-9 THC, delta-10 THC, and all other THC isomers. SB 645 would effectively ban all intoxicating hemp products while allowing low-dose CBD products to remain legal. House Bill 1782, filed by Representative Stephanie Klick, would establish a comprehensive regulatory framework without prohibition. The bill would create a licensing system administered by DSHS for hemp processors and retailers, require third-party laboratory testing for potency and contaminants, limit products to 10 milligrams of total THC per serving, require child-resistant packaging, prohibit sales to individuals under 21, and establish penalties for violations. HB 1782 would also impose a 10% excise tax on hemp-derived THC products, with revenue dedicated to substance abuse treatment programs. As of the July 2026 hearing, neither bill had advanced to a floor vote, though both remained active and eligible for consideration during the remainder of the session.

Market and Business Implications

A prohibition on hemp-derived THC products would eliminate a $1.2 billion market segment, force the closure of hundreds of small businesses, and redirect consumer demand to either the illicit market or neighboring states with legal access. The Texas hemp industry has grown rapidly since 2020, with market research firm BDSA estimating total sales of hemp-derived THC products reached $1.2 billion in 2025, up from approximately $400 million in 2022. The market supports an estimated 1,800 licensed businesses including cultivators, processors, manufacturers, and retailers, along with ancillary service providers such as testing laboratories, packaging companies, and distribution services. Total employment in the hemp sector is estimated at 12,000 full-time equivalent positions. The retail landscape includes dedicated hemp and CBD stores, smoke shops, convenience stores, and online retailers. Delta-8 THC products are available in approximately 4,500 retail locations across Texas, with the highest concentration in major metropolitan areas including Houston, Dallas-Fort Worth, San Antonio, and Austin. Average retail prices for delta-8 gummies range from $20 to $40 for a package of 10-20 pieces, with vape cartridges typically priced between $25 and $50. Wholesale pricing for delta-8 THC distillate—the concentrated oil used to manufacture finished products—declined significantly between 2021 and 2025 as production capacity increased and competition intensified. Wholesale prices fell from approximately $3,000 per kilogram in early 2021 to $400-$600 per kilogram by mid-2025, compressing profit margins for processors and manufacturers. Many businesses responded by expanding into other hemp-derived cannabinoids including delta-10 THC, THC-P, and HHC to differentiate their product offerings.

Impact on Multi-State Operators

Several multi-state cannabis operators with operations in legal markets have established hemp-derived THC businesses in Texas as a way to enter the state's market in the absence of legal marijuana. Curaleaf Holdings, one of the largest MSOs in the United States, operates Select Hemp brand products in Texas through partnerships with licensed hemp processors. Trulieve Cannabis Corp entered the Texas market in 2024 through the acquisition of a hemp processing license and retail locations. A prohibition would force these operators to exit the Texas market or pivot to non-intoxicating CBD products with significantly lower profit margins. The uncertainty created by pending legislation has already impacted investment decisions, with several planned facility expansions and retail openings placed on hold pending resolution of the regulatory status.

Tax Revenue Implications

The Texas Comptroller of Public Accounts estimated that hemp-derived THC product sales generated approximately $89 million in state sales tax revenue in fiscal year 2025, based on the state's 6.25% sales tax rate applied to $1.2 billion in retail sales, adjusted for online sales and tax compliance rates. Local jurisdictions collected an additional estimated $25-30 million in local sales taxes. A prohibition would eliminate this revenue stream while potentially increasing state costs associated with enforcement and prosecution. The Texas Department of Public Safety estimated that investigating and prosecuting violations of a hemp-derived THC ban would require approximately $15 million in additional annual funding for personnel, laboratory testing, and legal proceedings. Conversely, House Bill 1782's proposed 10% excise tax on hemp-derived THC products would generate an estimated $120 million in annual revenue if the market maintains its current size under a regulatory framework. The bill dedicates this revenue to substance abuse treatment programs, which proponents argue would address the public health concerns that motivate prohibition efforts.

Consumer Behavior Projections

Market analysts project that a prohibition would redirect consumer demand through several channels. An estimated 30-40% of current consumers would cease use entirely, either due to lack of access or unwillingness to engage with illicit markets. Another 30-40% would likely turn to unregulated illicit sources, including online vendors operating outside Texas jurisdiction and unlicensed local dealers. Approximately 20-30% of consumers would potentially relocate purchases to neighboring states with legal hemp-derived THC products or travel to Oklahoma, which has a legal adult-use marijuana market. The illicit market redirection would eliminate the tax revenue currently generated by legal sales while creating new public health risks associated with unregulated products. Historical precedent from alcohol prohibition and marijuana criminalization suggests that prohibition drives consumption underground rather than eliminating demand, particularly for products used by adults for therapeutic purposes.

Industry Consolidation and Adaptation

Some industry observers predict that even if prohibition legislation fails in 2026, the regulatory uncertainty and threat of future bans will drive consolidation in the Texas hemp market. Smaller operators with limited capital reserves may exit the market voluntarily or sell to larger companies with resources to navigate regulatory challenges. This consolidation pattern has occurred in other states that transitioned from unregulated hemp markets to strict regulatory frameworks. Several Texas hemp companies have already begun diversifying into non-intoxicating product lines including CBD topicals, pet products, and hemp-derived supplements to reduce dependence on delta-8 THC sales. This strategic pivot reflects industry recognition that the current regulatory status is unsustainable and that some form of restriction or regulation is likely regardless of whether outright prohibition succeeds.

What Experts Say

Medical professionals, toxicologists, legal scholars, and industry analysts offer sharply divergent assessments of the public health risks, legal questions, and policy options surrounding hemp-derived THC products in Texas. Dr. Peter Grinspoon, a physician and cannabis researcher at Harvard Medical School, has studied the delta-8 THC phenomenon nationally and provided written testimony to the Texas House Public Health Committee. According to Grinspoon's analysis, delta-8 THC produces psychoactive effects similar to delta-9 THC but with a potentially different side effect profile. Grinspoon noted that the lack of clinical research on delta-8 THC makes it difficult to assess long-term health impacts, and he expressed concern about the absence of regulatory oversight for product testing and quality control in unregulated markets like Texas. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has warned about the risks of high-potency THC products generally, including both marijuana and hemp-derived cannabinoids. In a 2024 research paper published in the New England Journal of Medicine, Volkow and colleagues documented associations between high-potency THC use and increased risk of cannabis use disorder, psychotic symptoms, and cognitive impairment

Update — July 18, 2026: Lawmakers Prepare New THC Product Ban Legislation

Texas legislators announced plans to introduce fresh legislation targeting hemp-derived THC products during the upcoming legislative session, according to the Marshall News Messenger. The renewed effort follows multiple failed attempts in previous sessions to close loopholes in the 2019 hemp legalization law that allowed delta-8 THC and similar intoxicating cannabinoids to proliferate across the state. Lawmakers cited ongoing concerns about product safety, youth access, and the lack of regulatory oversight as primary motivations for the new ban proposal.

The forthcoming bills are expected to explicitly prohibit all synthetically derived and intoxicating hemp cannabinoids, including delta-8, delta-10, THC-O, and HHC products currently sold in gas stations, smoke shops, and online retailers. Previous legislative attempts stalled due to disagreements over enforcement mechanisms, THC concentration thresholds, and exemptions for CBD products. Industry representatives have estimated the Texas hemp-derived THC market generates over $500 million annually, with thousands of retail locations and manufacturing facilities operating under the current legal ambiguity.

The proposed legislation would require retailers to remove all non-compliant products within 90 days of enactment or face civil penalties up to $10,000 per violation, according to draft language circulated among stakeholders. Law enforcement groups and medical cannabis advocates have expressed support for stricter regulation, while hemp industry coalitions are mobilizing opposition and preparing economic impact studies. The Texas Department of State Health Services has documented over 200 adverse event reports linked to hemp-derived THC products since 2021, including hospitalizations for severe vomiting and psychiatric episodes.

This matters because a successful ban would eliminate a significant revenue stream for thousands of Texas businesses while potentially driving consumers toward illicit markets or neighboring states with legal cannabis programs. The legislative push also reflects growing national momentum to regulate or prohibit intoxicating hemp products, with similar measures advancing in Louisiana, North Carolina, and Minnesota during 2026. Operators face immediate inventory risks and uncertain transition timelines if the ban advances through committee and floor votes in early 2027.